Wick Capital Partners’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$590K Buy
20,686
+10,369
+101% +$276K 0.07% 122
2026
Q2
$248K Buy
+10,317
New +$270K 0.04% 195
2022
Q2
– Sell
-7,036
Closed -$364K – 63
2022
Q1
$364K Buy
7,036
+300
+4% +$15.6K 0.24% 36
2021
Q4
$398K Buy
+6,736
New +$334K 0.31% 42

Other funds holding PFE

Wick Capital Partners's PFE Position: Q3 2026 in Review

Wick Capital Partners increased its Pfizer (PFE) stake by 101% in Q3 2026, buying an estimated $276K and bringing the position to 20,686 shares worth $590K. The position accounts for 0.07% of the portfolio, ranked #122.

Wick Capital Partners first reported a position in PFE in Q4 2021 and has held it in 4 quarters since. 2,886 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Wick Capital Partners held 20,686 shares of Pfizer worth $590K as of Q3 2026.
  • Wick Capital Partners bought 10,369 Pfizer shares in Q3 2026, an estimated $276K.
  • Pfizer made up 0.07% of Wick Capital Partners's portfolio in Q3 2026, its #122 holding.
  • Wick Capital Partners first reported a position in Pfizer in Q4 2021 and has held it in 4 quarters since.
  • 2,886 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Wick Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.